Guardant Health Inc
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| OPERATING ACTIVITIES: | ||
| Net loss | $(217,613) | $(206,304) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 21,335 | 20,976 |
| Operating lease costs | 15,226 | 14,708 |
| Stock-based compensation | 54,276 | 44,620 |
| Amortization of debt issuance costs | 1,290 | 1,287 |
| Amortization of premium (discount) on marketable debt securities | 107 | (3,085) |
| Unrealized losses (gains) on marketable equity securities | 45,539 | (67,879) |
| Impairment of non-marketable equity securities and other related assets | — | 29,054 |
| Other | 1,385 | 108 |
| Cash effect of changes in operating assets and liabilities: | ||
| Accounts receivable, net | (11,737) | 10,695 |
| Inventory, net | (5,035) | (8,931) |
| Prepaid expenses and other current assets, net | (8,661) | (891) |
| Other assets, net | (130) | 1,700 |
| Accounts payable and accrued liabilities | (15,025) | 16,512 |
| Operating lease liabilities | (17,696) | (14,970) |
| Deferred revenue | 12,453 | (6,056) |
| Net cash used in operating activities | (124,286) | (168,456) |
| INVESTING ACTIVITIES: | ||
| Purchase of marketable debt securities | — | (561,339) |
| Maturity of marketable debt securities | 35,000 | 492,700 |
| Purchase of non-marketable equity securities and other related assets | — | (1,227) |
| Purchase of property and equipment | (12,011) | (14,037) |
| Net cash provided by (used in) investing activities | 22,989 | (83,903) |
| FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock upon exercise of stock options | 2,577 | 220 |
| Proceeds from issuances of common stock under employee stock purchase plan | 7,212 | 6,697 |
| Taxes paid related to net share settlement of restricted stock units | (4,784) | (5,109) |
| Proceeds from follow-on public offering | — | 402,500 |
| Payment of offering costs related to follow-on public offering | — | (21,271) |
| Other | (181) | (37) |
| Net cash provided by financing activities | 4,824 | 383,000 |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (1,975) | (1,415) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (98,448) | 129,226 |
| Cash, cash equivalents and restricted cash—Beginning of period | 1,133,687 | 141,948 |
| Cash, cash equivalents and restricted cash—End of period | $1,035,239 | $271,174 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $933,694 | $271,073 |
| Restricted cash – included in cash, cash equivalents and restricted cash | 101,545 | 101 |
| Total cash, cash equivalents and restricted cash | $1,035,239 | $271,174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.